SS-31 Protocol

Evidence Level: Emerging Evidence

Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.

Human evidence: Multiple Phase 2/3 clinical trials across conditions including Barth syndrome and specific ophthalmic and cardiac indications, with mixed outcomes by endpoint.

Animal evidence: Extensive preclinical cardiolipin/mitochondrial-membrane research preceding human trials.

Introduction & Mechanism of Action

Mitochondria-targeted peptide studied in membrane energetics and oxidative stress.

Aromatic-cationic tetrapeptide that concentrates in the mitochondrial inner membrane and binds cardiolipin, studied for stabilizing membrane structure and improving electron-transport-chain efficiency under conditions of mitochondrial dysfunction.

Receptors/targets: No classical receptor — binds cardiolipin in the mitochondrial inner membrane

Areas of Research Interest

• Mitochondrial membrane biology
• Energetics research
• Condition-specific clinical programs

Benefits Reported in Research

• Mitochondrial-membrane research
• Oxidative-stress studies
• Energy-metabolism research

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 5–10 mg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on SS-31 reports administration at 5–10 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 10 mg vial with 2 mL bacteriostatic water, yielding a concentration of 5.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site erythema
• Headache (reported in some trial populations)

Contraindications

• Pregnancy
• Known hypersensitivity

Drug interactions

• Not well characterized outside of specific clinical trial populations

Safety

• Injection-site reactions reported in trials
• Condition-specific risks vary by the disease population studied

Clinical outcomes vary by disease and endpoint; mitochondrial mechanism alone does not establish broad anti-aging benefit.

Expected Results & Comparison

SS-31 has a more developed human clinical trial base than MOTS-C, but its trial outcomes have varied significantly by disease and endpoint — mitochondrial mechanism alone does not establish broad anti-aging benefit, and results in one condition do not generalize automatically to another.

References

Continue